Deserpidine - Generic Drug Details

What are the generic drug sources for deserpidine and what is the scope of freedom to operate?

Deserpidine is the generic ingredient in seven branded drugs marketed by Abbvie, Abbott, and Watson Labs, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for deserpidine.

Summary for deserpidine

US Patents:	0
Tradenames:	7
Applicants:	3
NDAs:	5
Drug Master File Entries:	4
Raw Ingredient (Bulk) Api Vendors:	58
Patent Applications:	1,282
DailyMed Link:	deserpidine at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for deserpidine

C02AA	Rauwolfia alkaloids
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for deserpidine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	HARMONYL	deserpidine	TABLET;ORAL	010796-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	ORETICYL 25	deserpidine; hydrochlorothiazide	TABLET;ORAL	012148-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	ORETICYL FORTE	deserpidine; hydrochlorothiazide	TABLET;ORAL	012148-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	ORETICYL 50	deserpidine; hydrochlorothiazide	TABLET;ORAL	012148-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbott	ENDURONYL	deserpidine; methyclothiazide	TABLET;ORAL	012775-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbott	ENDURONYL FORTE	deserpidine; methyclothiazide	TABLET;ORAL	012775-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	METHYCLOTHIAZIDE AND DESERPIDINE	deserpidine; methyclothiazide	TABLET;ORAL	088486-001	Aug 10, 1984		DISCN	No	No

Market Dynamics and Financial Trajectory for Deserpidine

Introduction

Deserpidine, an alkaloid derived from the plant Rauwolfia canescens, has been used primarily for its antihypertensive and antipsychotic properties. To understand the market dynamics and financial trajectory of this drug, it is essential to delve into its historical use, market competition, and the evolving pharmaceutical landscape.

Historical Context

Deserpidine was introduced in the mid-20th century as a treatment for hypertension and psychotic behavior. It was part of a class of drugs known as Rauwolfia alkaloids, which were widely used before the development of more modern antihypertensive agents[5].

Market for Antihypertensive Drugs

The market for antihypertensive drugs is highly competitive and has undergone significant changes over the years. In the 1950s and 1960s, drugs like deserpidine were among the few options available for managing hypertension. However, with the introduction of newer classes of drugs such as beta-blockers, ACE inhibitors, and calcium channel blockers, the market has become more diversified and competitive.

Product Differentiation and Promotion

In markets with few differentiated products, promotional expenditures can be unusually high. This was observed in the study on prescription drug markets, where sellers of oral diuretics, another class of antihypertensive drugs, spent a higher percentage of their sales on promotion compared to other markets[1].

Market Concentration and Competition

The antihypertensive drug market has seen varying levels of market concentration over the years. For instance, the market for oral diuretics, which is somewhat analogous to the market for antihypertensive drugs like deserpidine, showed high concentration among leading firms. However, non-leading firms in these markets often spent more on promotion to gain market share, indicating a competitive landscape where smaller players strive to compete with market leaders[1].

Financial Performance

The financial performance of deserpidine has been influenced by several factors, including its patent status, competition from newer drugs, and changes in medical practices.

Patent Status

Deserpidine does not have any patents, which has made it easier for generic versions to enter the market. This lack of patent protection has likely reduced its revenue over time as generic alternatives became available[5].

Competition from Newer Drugs

The introduction of newer antihypertensive drugs with better efficacy and safety profiles has significantly impacted the market share of deserpidine. Drugs like ACE inhibitors and calcium channel blockers have become preferred treatments due to their superior therapeutic outcomes, leading to a decline in the use and sales of deserpidine[5].

Changes in Medical Practices

Advancements in medical science and changes in treatment guidelines have also affected the financial trajectory of deserpidine. As medical practices evolve and new treatment options become available, older drugs like deserpidine are often relegated to secondary or tertiary treatment options, further reducing their market share and revenue.

Current Market Status

Today, deserpidine is no longer a leading antihypertensive drug. Its use has been largely supplanted by more modern and effective treatments. The drug is still available in some markets, often in combination with other antihypertensive agents like methyclothiazide, but its sales are significantly lower than in its heyday[5].

Pharmacoeconomic Considerations

From a pharmacoeconomic perspective, the cost-effectiveness of deserpidine compared to newer drugs is a critical factor. Newer antihypertensive drugs, despite being more expensive, often offer better outcomes and fewer side effects, making them more cost-effective in the long run. This has further eroded the market position of deserpidine.

Regulatory and Clinical Trial Landscape

Deserpidine has not been involved in recent clinical trials, and its regulatory status remains largely unchanged. The lack of ongoing clinical trials or regulatory approvals for new indications has meant that the drug has not seen any significant resurgence in its market position[5].

Conclusion

The market dynamics and financial trajectory of deserpidine reflect the broader trends in the pharmaceutical industry. Here are the key points:

• Historical Significance: Deserpidine was once a significant player in the antihypertensive market but has been largely replaced by newer drugs.
• Market Competition: The antihypertensive drug market is highly competitive, with newer drugs offering better efficacy and safety profiles.
• Financial Performance: The lack of patent protection, competition from newer drugs, and changes in medical practices have all contributed to a decline in the financial performance of deserpidine.
• Current Market Status: Deserpidine is no longer a leading antihypertensive drug and is often used in combination with other agents or in niche markets.
• Pharmacoeconomic Considerations: Newer antihypertensive drugs are generally more cost-effective despite higher costs.

Key Takeaways

• Deserpidine's market share has declined significantly due to the introduction of newer antihypertensive drugs.
• The lack of patent protection has allowed generic versions to enter the market, further reducing revenue.
• Changes in medical practices and treatment guidelines have favored newer drugs over deserpidine.
• Deserpidine is still available but is no longer a primary treatment option for hypertension.

FAQs

1. What is the primary use of deserpidine? Deserpidine is primarily used to treat hypertension and has antipsychotic properties.

2. Why has the use of deserpidine declined? The use of deserpidine has declined due to the introduction of newer antihypertensive drugs with better efficacy and safety profiles.

3. Does deserpidine have any patents? No, deserpidine does not have any patents, which has allowed generic versions to enter the market.

4. How does deserpidine work? Deserpidine works by inhibiting the ATP/Mg²⁺ pump responsible for the sequestering of neurotransmitters into storage vesicles, thereby controlling nerve impulses and lowering blood pressure[5].

5. Is deserpidine still available in the market? Yes, deserpidine is still available, often in combination with other antihypertensive agents, but its use is significantly reduced compared to its peak.